. Design of the study, acquisition of data, critical revising and final approval of the version to be published.
Introduction
The trace elements zinc (Zn) and copper (Cu) are essential for human health. Dietary factors, including a wide range of phytate intakes, cellular location, cell-specific expression, and regulation of the transporters involved in enteric Zn absorption are important for bioavailability this mineral 1 . Approximately 70% of circulating Zn is bound to serum albumin 2 . Zn is a constituent of more than 300 enzymes involved in a broad spectrum of activities, including anti-inflammatory and antioxidant effects 3 and genetic transcription regulation 4 . Dietary Cu is absorbed mainly in the duodenum and is chelated by metallothioneins in the cytoplasm of cells 5 . Cu binds to proteins involved in a variety of biological processes 6 such as the formation, maturation and stabilization of connective tissues and structure of the extracellular matrix 7 . Cu is involved in the detoxification of reactive oxygen species as it binds to metallothioneins under reducing conditions and influences the activity of antioxidant enzymes 6 . Cu is also essential for the immune response, including the production ofIL-2 by activated lymphocytic cells 7 .
The Cu/Zn ratio has been correlated with nutritional status in institutionalized elderly 8 and patients under peritoneal dialysis 9 .
Also, this ratio is considered as a marker for asthma severity 10 and prostate cancer detection 11 . In the elderly, increased Cu/Zn ratio was a predictive factor of mortality and it was associated with reduced serum albumin and increased inflammatory markers, like C-reactive protein and erythrocytes sedimentation rate 12 .
Calprotectin (S100A8/A9) accounts for more than 60% of total soluble proteins in the cytoplasm of neutrophils 13 .
Serum calprotectin has been suggested as a biomarker of chronic inflammation 14 , and to be correlated with acute phase response markers' concentrations 15 . The release of calprotectin by activated leukocytes 13 precedes the increase in liver protein synthesis in response to inflammatory stress 13, 15 . In view of the detection of early acute inflammatory changes, the simultaneous determination of calprotectin and hepatic markers levels would be clinically useful for monitoring several inflammatory conditions 15 .
Colorectal cancer is one of the major causes of death by cancer in the western world, and surgery for excision of the primary tumor is undertaken in 80% of patients 16 . Preoperative colorectal cancer patients are not usually considered to be at risk of malnutrition 16 . Although these patients may be classified as overweight or obese according to the BMI, some of them have a weight loss greater than 10%, indicating a certain degree of malnutrition 16 . So far, to our knowledge, there is no available study correlating nutritional status and inflammatory status with Cu/Zn ratio in colorectal cancer. The present study aimed to compare and correlate the plasma Cu/Zn ratio with nutritional and inflammatory status in colorectal cancer patients during the perioperative period.
Methods
The 
Assessment of food intake and body composition
At the beginning of the study, a semi-quantitative food frequency questionnaire (SQFFQ) was applied to evaluate subjects' habitual food intake in the preceding six months. Daily intake of nutrients was determined by using the software (NutWin, version 2.5a, UNIFESP, São Paulo, Brazil). 
Biochemical analyses
Routine laboratory analyses included serum levels of total protein and albumin (colorimetry), determined with an automatic biochemical analyzer (Konelab 6.0, Winer, Argentina).
Hemoglobin levels were determined by photometry, using the ABX Pentra DX120 (Horiba Ltd, Kyoto, Japan copper were set at 70-140µg/dL and 50-120µg/dL, respectively.
Statistical analysis
Mann-Whitney U-test was used for comparisons between demographic and clinical features of groups, and the results are shown as geometric mean and 95% confidence interval. Spearman's correlation coefficient was used for correlation analyses between variables and the Cu/Zn ratio. Data analyses were performed with Statistica software (version 8.0; StatSoft Inc., Tulsa, OK, USA). The level of significance was set at 5%.
Results
Food intake, body composition and laboratory data are shown in Table 1 . Energy, protein and zinc intake was similar in the Cancer Group as compared with controls in the six months prior to the study. Individuals of the Cancer Group exhibited lower body weight, BMI and fat mass as compared with the Control Group. Colorectal cancer patients presented lower hemoglobin, total protein and albumin serum concentrations than controls. Plasma Cu concentrations were higher in patients with colorectal cancer than in controls, and plasma Zn was similar between groups. Hence, a higher Cu/Zn ratio was found in the Cancer Group than in the Control Group. between Cu/Zn ratio and Zn intake (r=-0.24), serum albumin (r=-0.37) and hemoglobin (r=-0.42), and a weak positive correlation between Cu/Zn ratio and serum calprotectin (r=0.28).
Discussion
This study has found that patients with colorectal cancer presented lower body weight, BMI and fat mass compared to healthy volunteers. Besides, the Cancer Group had lower hemoglobin, total protein and albumin serum levels, and higher serum calprotectin, plasma Cu and Cu/Zn ratio than controls.
The assessment of habitual food intake by the SQFFQ revealed that the nutrient intake in patients with colorectal cancer was similar than in healthy controls, including Cu and Zn, met the Dietary Reference Intakes (DRI). This result is different from the study reported by Ravasco et al. (2004) 17 , which showed that patients in the perioperative period of head and neck, esophagus, stomach and colorectal tumor surgery had low nutrient intake as assessed by the 24-hour recall method. The discrepancy between results may be explained by differences in the methods used to estimate food consumption in these studies, although some studies show correlations between nutrient intakes measured by a frequency questionnaire and multiple 24-hour dietary recalls or diet records 18 . Anthropometric data of patients were similar to those found in the literature 19 . The prevalence of nutritional disturbances in colorectal cancer patients depends on the definitions of nutritional risk and malnutrition adopted at the time of evaluation 19, 20 . Some studies have demonstrated a high prevalence of overweight and obesity in these patients 19 , indicating little effect on nutritional status, differently from other advanced neoplasms in the gastrointestinal tract 21 . However, it is worth mentioning that BMI may continue within normal range even after weight loss. History of weight loss was evaluated by the Subjective Global Assessment (SGA), which showed that 35% of patients with colorectal cancer were moderately or severely malnourished or at nutritional risk 20 . On the other hand, the Malnutrition Screening Tool (MUST) and the Nutritional Risk Index (NRI) identified undernutrition in 44% and 53% of colorectal cancer patients, respectively 20 .
In colorectal cancer, food intake is slightly affected with no digestive or absorptive disturbances, and intestinal obstruction occurs only in advanced cases of the disease. On the other hand, inflammatory pathways are constitutively active in most cancers 21 and may lead to reductions in body protein levels, regardless of food intake. Although colorectal tumors trigger inflammatory stress responses, albumin levels are generally within normal range or slightly reduced 22 . In this context, increased calprotectin levels in our cancer patients indicate its possible role in inflammationassociated carcinogenesis 14 . This increase has been related to the persistent innate immune cell activation in many epithelial cancers 14 and detection of calprotectin-positive myeloid cells within the tumor stroma in colorectalcancer 23 .
Also, our findings regarding Cu plasma concentrations are in accordance with those observed in uterine cervical 24 and gut cancer 25 , reporting higher levels of Cu as compared with healthy volunteers. 6, 7 . During stress and trauma conditions, the proinflammatory cytokines IL-1 and IL-6 stimulate the synthesis of acute-phase reactive protein by the liver 7 , which may explain the increase in plasma Cu levels. Zn deficiency was not observed in our patients, different from previous studies that reported low Zn levels in uterine cervical 24 and gut cancer 25 patients.
A greater Cu/Zn ratio occurred in our Cancer Group than in the Control Group, similarly to previous studies on uterine cervical cancer 24 . Tuberculosis patients had a high level of copper and copper/zinc ratio when compared to healthy controls, and the alteration was more pronounced in those coinfected with HIV 27 .
The Cu/Zn ratio has been pointed out as a diagnosis and prognosis factor of inflammation in lymphoma and leukemia 28 , gastric 29 and breast cancer 30 .
A limitation of this study was the relatively small numbers of patients and controls, although the Cancer Group was homogeneous regarding tumor site and histological diagnosis.
Despite small sample size, we found negative correlations between the Cu/Zn ratio and the nutritional parameters in patients with cancer. In subjects under peritoneal dialysis, elevated Cu/Zn levels were associated with undernutrition, increased oxidative stress, inflammation and deterioration of immune function
9
. The Cu/Zn ratio increased proportionally with increasing levels of prostate specific antigen in patients with prostate cancer
11
, and correlated with lipid peroxidation markers in asthma patients 10 .
Conclusion
This study has shown that the Cu/Zn ratio and the inflammatory marker calprotectin are increased, and protein levels decrease in patients with colorectal cancer. These findings suggest that the Cu/Zn ratio may be an inflammatory-nutritional biomarker, resulting from the inflammatory response to the tumor process.
Further work might investigate whether other immunological and inflammatory markers could affect trace element status and clinical progression in cancer patients.
